About Adaptive Biotechnologies
We are a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with unprecedented scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery.
We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients11-23-2020 at 8:00 AM EST
Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections11-13-2020 at 8:00 AM EST
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio11-10-2020 at 4:13 PM EST
- 11-10-2020 at 4:30 PM EST
- 09-24-2020 at 8:30 AM EDT
- 09-15-2020 at 1:15 PM EDT